{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:13:09Z","timestamp":1790802789409,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ijcard.2016.06.150","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T13:06:54Z","timestamp":1466946414000},"page":"445-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Medical treatment of stable angina: A tailored therapeutic approach"],"prefix":"10.1016","volume":"220","author":[{"given":"Athanasios J.","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas E.","family":"Poulimenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolis S.","family":"Kallistratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lopez-Sendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Dechend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Camm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.06.150_bb0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1377\/hlthaff.26.1.38","article-title":"An overview of cardiovascular disease burden in the United States","volume":"26","author":"Mensah","year":"2007","journal-title":"Health Aff."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0010","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/CIRCULATIONAHA.109.192667","article-title":"Heart disease and stroke statistics\u20142010 update: a report from the American Heart Association","volume":"121","author":"Writing Group Members","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/eurheartj\/ehp605","article-title":"Controversies in cardiovascular medicine: chronic stable coronary artery disease: drugs vs. revascularization","volume":"31","author":"Simoons","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM200103013440906","article-title":"Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization","volume":"344","author":"Hemingway","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0025","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM200104123441502","article-title":"Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease","volume":"344","author":"Serruys","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0030","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0735-1097(03)00951-3","article-title":"Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy","volume":"42","author":"Henderson","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0035","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa072771","article-title":"Effect of PCI on quality of life in patients with stable coronary disease","volume":"359","author":"Weintraub","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0040","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1067\/mhj.2002.125505","article-title":"Angina 1year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry","volume":"144","author":"Holubkov","year":"2002","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-152-6-201003160-00007","article-title":"Meta-analysis: effects of percutaneous coronary intervention versus medical therapy on angina relief","volume":"152","author":"Wijeysundera","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jchf.2013.03.003","article-title":"Nitrate therapy for heart failure: benefits and strategies to overcome tolerance","volume":"1","author":"Gupta","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0055","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Members","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0002-8703(95)90281-3","article-title":"Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial","volume":"129","author":"Ezekowitz","year":"1995","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00192354","article-title":"Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris","volume":"49","author":"Boman","year":"1995","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0070","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2165\/00003495-199651050-00007","article-title":"Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease","volume":"51","author":"Brogden","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0075","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0080","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/01.CIR.92.5.1326","article-title":"Nifedipine. Dose-related increase in mortality in patients with coronary heart disease","volume":"92","author":"Furberg","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/pcad.2000.7010","article-title":"Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies","volume":"43","author":"Opie","year":"2000","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0090","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group","volume":"335","author":"Packer","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0095","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.amjmed.2008.09.043","article-title":"Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis","volume":"122","author":"Bangalore","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/oxfordjournals.eurheartj.a014695","article-title":"Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)","volume":"17","author":"Rehnqvist","year":"1996","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0105","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1161\/CIR.0b013e318277d6a0","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0110","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ijcard.2016.06.150_bb0115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1074248415608011","article-title":"Does Oral Beta-Blocker Therapy Improve Long-Term Survival in ST-Segment Elevation Myocardial Infarction With Preserved Systolic Function? A Meta-Analysis","volume":"21","author":"Misumida","year":"2016","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0120","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","article-title":"\u03b2-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0125","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0130","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/eurheartj\/eht384","article-title":"Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"35","author":"M\u00fcnzel","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00019501-200212000-00008","article-title":"Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis","volume":"13","author":"Klein","year":"2002","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0140","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis","volume":"22","author":"Belsey","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0145","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/0735-1097(89)90216-7","article-title":"Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina","volume":"13","author":"DeMots","year":"1989","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0150","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0002-9149(93)90292-K","article-title":"Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris","volume":"72","author":"Chrysant","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0155","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/01.CIR.91.5.1368","article-title":"Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group","volume":"91","author":"Parker","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0160","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.281.20.1927","article-title":"Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina","volume":"281","author":"Heidenreich","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0165","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/01.RES.0000184694.03262.6d","article-title":"Explaining the phenomenon of nitrate tolerance","volume":"97","author":"M\u00fcnzel","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0170","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/01.CIR.0000036742.52907.91","article-title":"The puzzle of nitrate tolerance: pieces smaller than we thought?","volume":"106","author":"Gori","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/eurheartj\/ehp457","article-title":"Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events","volume":"31","author":"Ambrosio","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0180","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0185","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0190","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0195","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","article-title":"Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris","volume":"67","author":"Ruzyllo","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0200","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0205","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial","volume":"53","author":"Wilson","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0210","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0215","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0220","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0225","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0235","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Weisz","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0240","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2165\/00003495-200060040-00007","article-title":"Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects","volume":"60","author":"Markham","year":"2000","journal-title":"Drugs"},{"issue":"Suppl. 3","key":"10.1016\/j.ijcard.2016.06.150_bb0245","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1097\/00005344-199206203-00013","article-title":"Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients","volume":"20","author":"D\u00f6ring","year":"1992","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00878320","article-title":"A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris","volume":"7","author":"Di Somma","year":"1993","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0255","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0002-9149(99)00025-9","article-title":"Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris","volume":"83","author":"Rajaratnam","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0260","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","article-title":"Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial","volume":"359","author":"IONA Study Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0265","unstructured":"\/C:\/Users\/man\/Downloads\/11 12 15 Sanofi Nicorandil Alert (1).pdf n.d."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0270","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.1994.tb04276.x","article-title":"Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group","volume":"37","author":"Detry","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0275","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijcard.2015.08.045","article-title":"Unresolved issues in the management of chronic stable angina","volume":"201","author":"Camm","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003614.pub2","article-title":"Trimetazidine for stable angina","author":"Ciapponi","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0285","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0003319714530040","article-title":"Trimetazidine and cardioprotection: facts and perspectives","volume":"66","author":"Tsioufis","year":"2015","journal-title":"Angiology"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0290","unstructured":"Trimetazidine. Questions and answers on the review of medicines containing trimetazidine (20mgtablets, 35mg modified release tablet and 20mg\/ml oral solution) n.d."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0295","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1053\/euhj.1999.2439","volume":"21","year":"2000","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0300","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/eurheartj\/eht377","article-title":"New ESC guidelines published on stable coronary artery disease","volume":"34","author":"Taylor","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0305","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/eurheartj\/ehs289","article-title":"Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry","volume":"33","author":"Steg","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2014.06.052","article-title":"Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry","volume":"176","author":"Tendera","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/1479164115609028","article-title":"Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: a review of the evidence","volume":"13","author":"Ambrosio","year":"2016","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0320","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2337\/dc14-2629","article-title":"Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes","volume":"38","author":"Eckel","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0325","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2337\/dc09-2334","article-title":"Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome","volume":"33","author":"Chisholm","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0330","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0335","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0340","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/fca.14.51","article-title":"Vasodilator \u03b2-blockers: a different class of antihypertensive agents?","volume":"10","author":"Kallistratos","year":"2014","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0345","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HJH.0b013e3282f283c9","article-title":"A comparison of atenolol and nebivolol in isolated systolic hypertension","volume":"26","author":"Dhakam","year":"2008","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0350","first-page":"283","article-title":"Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients","volume":"8","author":"Lacourci\u00e8re","year":"1994","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0355","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0360","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1007744109064","article-title":"The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1","volume":"13","author":"Szwed","year":"1999","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0365","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"European Heart Rhythm Association","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0370","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/eurheartj\/eht429","article-title":"Calcium channel blockers improve exercise capacity and reduce N-terminal pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation","volume":"35","author":"Ulimoen","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0375","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0380","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0385","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2011.04.017","article-title":"Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting","volume":"108","author":"Miles","year":"2011","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.06.150_bb0390","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCEP.115.002856","article-title":"The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism","volume":"8","author":"Reiffel","year":"2015","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0395","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0400","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0405","unstructured":"PRAC recommends measures to reduce risk of heart problems with Corlentor\/Procoralan (ivabradine) n.d."},{"issue":"10022","key":"10.1016\/j.ijcard.2016.06.150_bb0410","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0415","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","volume":"27","author":"Mancia","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0420","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000362381","article-title":"The J-curve in arterial hypertension: fact or fallacy?","volume":"129","author":"Tsika","year":"2014","journal-title":"Cardiology"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0425","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMcp1502240","article-title":"Chronic stable angina","volume":"374","author":"Ohman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0430","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/HYPERTENSIONAHA.113.01922","article-title":"Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement","volume":"63","author":"Mancia","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0435","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.amjcard.2010.05.006","article-title":"Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events","volume":"106","author":"Chrysant","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0440","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jama.1991.03460040065031","article-title":"The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?","volume":"265","author":"Farnett","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0445","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","article-title":"Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?","volume":"144","author":"Messerli","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0450","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/HJH.0b013e32832d7370","article-title":"Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study","volume":"27","author":"Sleight","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0455","doi-asserted-by":"crossref","first-page":"i717","DOI":"10.1136\/bmj.i717","article-title":"Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses","volume":"352","author":"Brunstr\u00f6m","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0460","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0465","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0470","unstructured":"The SPRINT Trial: Cons - American College of Cardiology n.d. http:\/\/www.acc.org\/latest-in-cardiology\/articles\/2015\/12\/01\/10\/04\/the-sprint-trial-cons (accessed March 8, 2016)."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0475","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.115.05463","article-title":"Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice","volume":"66","author":"Corrao","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0480","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","article-title":"Better compliance to antihypertensive medications reduces cardiovascular risk","volume":"29","author":"Corrao","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0485","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijcard.2012.07.001","article-title":"Angina pectoris in women: focus on microvascular disease","volume":"163","author":"Zuchi","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0490","doi-asserted-by":"crossref","unstructured":"Send\u00f3n JL, Lee S, Cheng ML, Ben-Yehuda O, CARISA study investigators. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur. J. Prev. Cardiol. 2012;19:952\u2013959.","DOI":"10.1177\/2047487312450133"},{"key":"10.1016\/j.ijcard.2016.06.150_bb0495","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjcard.2006.07.052","article-title":"Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials","volume":"99","author":"Wenger","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.150_bb0500","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","article-title":"Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease","volume":"4","author":"Mehta","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"19","key":"10.1016\/j.ijcard.2016.06.150_bb0505","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehv647","article-title":"A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve","volume":"37","author":"Bairey Merz","year":"2016","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316311585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316311585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T20:00:14Z","timestamp":1536609614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316311585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":101,"alternative-id":["S0167527316311585"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.150","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical treatment of stable angina: A tailored therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}